Source: DailyAlts

GreenLight: Venture Capital: GreenLight Biosciences Notches $102M to Expand RNA-based Products

GreenLight Biosciences, which is pioneering technology to create cell-free, high-performing natural RNA products, announced its raise of $102 million in an oversubscribed Series D funding round led by Chinese investment firm Morningside Ventures.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Andrey J. Zarur's photo - President & CEO of GreenLight

President & CEO

Andrey J. Zarur

CEO Approval Rating

86/100

GreenLight is a bio-performance company that develops RNA-based healthcare products for agriculture and pharmaceutical applications. Read more